Blood Tests Track Microrna Levels in Patients With Brain Tumors
Blood samples over time from adults with grade 4 glioma after surgery.
Plain-language title generated from the registry record
Registry title: Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
Key facts
- Where
- Caen, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a grade 4 diffuse glioma who had brain surgery at Caen University Hospital. Blood samples are used to follow microRNA levels.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Grade 4 diffuse glioma.
- Earlier treatment
- Must have had surgery in the neurosurgery department of Caen University Hospital. People who only had a biopsy cannot join.
Main reasons for not taking part
- Only had a biopsy, no surgical removal
- Grade 1 circumscribed glioma, or grade 2 or 3 diffuse glioma
- Other non-glial or glioneuronal tumours
- Under 18 years old, or a minor under guardianship or protection
- Not affiliated to a social security scheme, or opposed to the study
Read by machine on 12 November 2026.
Where in France
- Arthur LeclercCaen, FranceContact: Arthur Leclerc, MD, MScTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Caen
- Trial code
- NCT06203496
- Record updated
- 12 January 2024
- Original description
MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023). They are widely implicated in oncogenesis, and in particular in mechanisms promoting cell migration, invasion and proliferation (Romano et al., 2021). Several preliminary studies have shown that serum levels of pro-oncogenic microRNAs correlate with tumor rates in gliomas (Jones et al., 2021; Levallet et al., 2022; Morokoff et al., 2020). Morokoff's study showed encouraging but insufficient results on the possibility of using microRNAs to differentiate radionecrosis versus recurrence. These results need to be consolidated prospectively, with homogeneous samples taken from all patients.Read full original descriptionShow less
Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023). They are widely implicated in oncogenesis, and in particular in mechanisms promoting cell migration, invasion and proliferation (Romano et al., 2021). Several preliminary studies have shown that serum levels of pro-oncogenic microRNAs correlate with tumor rates in gliomas (Jones et al., 2021; Levallet et al., 2022; Morokoff et al., 2020). Morokoff's study showed encouraging but insufficient results on the possibility of using microRNAs to differentiate radionecrosis versus recurrence. These results need to be consolidated prospectively, with homogeneous samples taken from all patients.
The aim of this study is to describe the evolution over time of plasma levels of pro-oncogenic microRNAs, after surgery for grade 4 glioma, in order to assess whether they can be used to identify false-positive recurrences on MRI (radionecrosis).
Inclusion: Major patient; Grade 4 diffuse glioma; Surgery in the neurosurgery department of Caen University Hospital; Patient affiliated to a social security scheme; Patient followed at Caen University Hospital; No opposition from patient.
Exclusion: - Patients who underwent biopsy (lack of material for study, limited interest of monitoring for these patients without surgical excision); Patients with grade 1 circumscribed glioma or grade 2 or 3 diffuse glioma; Other non-glial histologies, glioneuronal histology; Minor patients; Patient not affiliated to a social security scheme; A minor under guardianship or protection; Patient opposed to study.